Georgia Expands Medical Cannabis Potency Limits Under New Legislation

Georgia's medical cannabis program expands access to higher-potency products following implementation of revised state legislation. The updated law removes previous restrictions on THC concentrations, allowing licensed dispensaries to offer stronger formulations to registered patients. This regulatory shift brings Georgia closer to potency standards adopted in more mature medical cannabis markets across the country.

The policy change addresses longstanding complaints from patients and advocacy groups who argued that low-potency limits forced consumers to purchase larger quantities or seek alternative sources. Georgia's original medical cannabis framework, among the most restrictive in the nation, limited THC content to 5% for most products. The revised regulations eliminate these caps while maintaining the state's closed-loop system that restricts cultivation and distribution to a small number of licensed operators.

Georgia's medical cannabis market generates limited revenue compared to adult-use states, with only a handful of licensed cultivation facilities and dispensaries serving roughly 25,000 registered patients. The potency expansion could drive higher per-patient spending and improve unit economics for existing operators, though the state's restrictive qualifying conditions list continues to limit patient enrollment growth.

The regulatory update reflects broader trends across southeastern states gradually expanding medical cannabis access. Florida, Louisiana, and Arkansas have similarly revised potency restrictions over the past two years as state programs mature. However, Georgia maintains prohibition on smokable flower products, distinguishing it from neighboring markets that allow broader product categories.

Investors tracking multi-state operators with Georgia exposure should monitor whether increased potency drives meaningful revenue growth in what remains a constrained market. The state's limited license structure creates high barriers to entry but also caps total addressable market size until lawmakers expand qualifying conditions or consider adult-use legalization discussions that remain politically unlikely in the near term.